| Drug Name |
Clofarabine |
| Drug ID |
BADD_D00495 |
| Description |
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. |
| Indications and Usage |
For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01BB06 |
| DrugBank ID |
DB00631
|
| KEGG ID |
D03546
|
| MeSH ID |
D000077866
|
| PubChem ID |
119182
|
| TTD Drug ID |
D0R5RR
|
| NDC Product Code |
67430-250; 49315-003; 60505-6166; 72266-108; 0024-5860; 68083-386; 54893-0028; 70121-1236; 67457-546; 71288-128; 0955-1746; 42973-173; 76055-0016; 63323-572; 65129-1278; 82920-024; 43598-309; 17337-0310; 55150-326 |
| UNII |
762RDY0Y2H
|
| Synonyms |
Clofarabine | 2-Chloro-9-(2-deoxy-2-fluoroarabinofuranosyl)adenine | Cl-F-ara-A | 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arbinofuranosyl)adenine | 2-Chloro-2'-arabino-fluoro-2'-deoxyadenosine | 2 Chloro 2' arabino fluoro 2' deoxyadenosine | 2-Chloro-2'-fluoroarabino-2'-deoxyadenosine | 2 Chloro 2' fluoroarabino 2' deoxyadenosine | 9H-Purin-6-amine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)- | Clolar | Evoltra | Clofarex |
